Researchers studying multiple sclerosis(MS) have long been looking for the specific molecules in the body that cause lesions in myelin, the fatty, insulating cells that sheathe the nerves.

A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident. There are currently no FDA-approved treatments or prophylactics available to manage the condition, ...

NEW YORK, APRIL 4, 2012 A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident. There are currently no FDA-approved treatments or ...

(Memorial Sloan-Kettering Cancer Center) A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident. There are currently no FDA-approved treatments or prophylactics available ...

Creating a radioactive antibody fragment may allow scientists to identify fat and debris deposits in artery walls that are most likely to rupture and cause heart attacks, according to a new study in Circulation: Research, an American Heart Association journal. Of the more than 17 million annual cardiovascular deaths worldwide, ...

Women who have been infected by two different strains of HIV from two different sexual partners - a condition known as HIV superinfection - have more potent antibody responses that block the replication of the virus compared to women who've only been infected once. These findings, by researchers at Fred ...

Low-density lipoprotein-cholesterol (LDL-C) is the "bad" cholesterol, and despite many drugs including statins available to doctors, patients often have trouble reducing their blood level of LCL-C. Sanofi and Regeneron presented data at The American College of Cardiology Meeting on 26th March 2012, showing an impressive reduction using their new antibody ...

A single antibody caused tumors from seven different human cancers transplanted into mice to shrink or disappear, according to a new study led by Stanford University School of Medicine in the US. The researchers hope to repeat this dramatic finding with tests in humans within the next ...

Human tumors transplanted into laboratory mice disappeared or shrank when scientists treated the animals with a single antibody, according to a new study from the Stanford University School of Medicine. The antibody works by masking a protein flag on cancer cells that protects them from macrophages and other cells in ...

A novel monoclonal antibody identified in a new study dramatically lowered circulating LDL cholesterol by 40 percent to 72 percent, a development with potential to provide a new option for patients who are resistant to cholesterol-lowering drugs such as statins or to the current standard of care, according to research ...

(American College of Cardiology) A novel monoclonal antibody identified in a new study dramatically lowered circulating LDL cholesterol by 40 percent to 72 percent, a development with potential to provide a new option for patients who are resistant to cholesterol-lowering drugs such as statins or to the current standard of ...

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.